AVTX
NASDAQ · Biotechnology
Avalo Therapeutics Inc
$18.41
-0.60 (-3.16%)
Open$18.88
Previous Close$19.01
Day High$19.00
Day Low$18.40
52W High$24.27
52W Low$3.39
Volume—
Avg Volume4.36M
Market Cap937.77M
P/E Ratio—
EPS$-6.04
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+78.8% upside
Current
$18.41
$18.41
Target
$32.91
$32.91
$27.78
$32.91 avg
$47.11
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 224.1K | 1.51M | 36.29M |
| Net Income | -297,381,524 | -1,803,526,762 | 8.09M |
| Profit Margin | -132,642.4% | -126,010.3% | 22.3% |
| EBITDA | -275,804,159 | -1,765,592,662 | 9.50M |
| Free Cash Flow | — | — | 4.67M |
| Rev Growth | -85.2% | -85.2% | +16.8% |
| Debt/Equity | 0.03 | 0.03 | 0.47 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |